Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Benzalkonium Chloride Antimicrobial Handwash Kills 98% Of Staph - ILTC

This article was originally published in The Tan Sheet

Executive Summary

Inclusion of benzalkonium chloride as a Category I ingredient in the tentative final monograph for OTC topical antimicrobial drug products is requested by International Laboratory Technology Corp. in a citizen petition submitted to FDA April 6.

You may also be interested in...



Benzalkonium chloride

FDA should not clear the ingredient for chronic use in health care antiseptic drug products due to a lack of data demonstrating long-term safety, Lonza's counsel says in an Aug. 3 letter. Responding to a citizen petition filed by International Laboratory Technology Corp. requesting GRAS/E status for the ingredient in OTC topical antimicrobial products, Lonza notes the agency has required data on chronic toxicity for a number of ingredients evaluated in the health care antiseptic drug products monograph, but the studies submitted by ILTC do not address long-term use. FDA currently considers benzalkonium chloride (.11%-.13%) a Category III ingredient - data insufficient to demonstrate safety/efficacy - except for short-term use (1"The Tan Sheet" April 24, p. 9)

Benzalkonium chloride

FDA should not clear the ingredient for chronic use in health care antiseptic drug products due to a lack of data demonstrating long-term safety, Lonza's counsel says in an Aug. 3 letter. Responding to a citizen petition filed by International Laboratory Technology Corp. requesting GRAS/E status for the ingredient in OTC topical antimicrobial products, Lonza notes the agency has required data on chronic toxicity for a number of ingredients evaluated in the health care antiseptic drug products monograph, but the studies submitted by ILTC do not address long-term use. FDA currently considers benzalkonium chloride (.11%-.13%) a Category III ingredient - data insufficient to demonstrate safety/efficacy - except for short-term use (1"The Tan Sheet" April 24, p. 9)

Topical Antimicrobial Test Standards Created By Third Party Possible - FDA

FDA is willing to consider working with third-party standard-setting organizations to develop testing methodologies for the healthcare antiseptic products final monograph.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS091112

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel